The narsoplimab program hasn't proceeded as swimmingly as investors thought.
Compare OMER Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
News & Analysis: Omeros
The biotech stock was part of a larger Wall Street sell-off.
The biopharma announced the pricing of a public offering of common stock and debt offering.
Two major catalysts on the horizon could send Omeros' stock soaring. What should investors think?
OMER earnings call for the period ending March 31, 2020.
OMER earnings call for the period ending December 31, 2019.
The company reported full-year 2019 operating results and a separate update from the pipeline.
Single-arm trial data for narsoplimab isn't nearly as exciting as it used to be.
OMER earnings call for the period ending September 30, 2019.
Find out why these stocks missed out on the market rally.